PrEP demo project finds the people at highest HIV risk generally take PrEP most consistently

nam, 27 July 2015

An open-label demonstration project of Truvada pre-exposure prophylaxis (PrEP) in the United States has found generally high retention and adherence rates, with the highest adherence among those at the highest risk of HIV.

Read more here